SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol
Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, rando...
Main Authors: | Caroline McCarthy, Joseph Sacco, Stefano Fedele, Michael Ho, Stephen Porter, Triantafillos Liloglou, Bill Greenhalf, Max Robinson, Bridget Young, Silvia Cicconi, Seema Chauhan, Binyam Tesfaye, Richard Jackson, Frances Sherratt, Richard Shaw |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-021-05373-8 |
Similar Items
-
The menacing side of valproate: A case series of valproate-induced hyperammonemia
by: Deeksha Elwadhi, et al.
Published: (2017-01-01) -
Platelet Function and Valproate
by: J Gordon Millichap
Published: (1999-03-01) -
Topiramate-Induced Valproate Toxicity
by: J Gordon Millichap
Published: (2002-04-01) -
Cognitive Effects of Topiramate and Valproate
by: J Gordon Millichap
Published: (2003-06-01) -
Valproate-induced Hyperammonemic Encephalopathy
by: Hsiao-Feng Chou, et al.
Published: (2008-10-01)